These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24352359)

  • 21. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
    Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
    Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.
    Arnaud M; Bobisse S; Chiffelle J; Harari A
    Front Immunol; 2021; 12():701636. PubMed ID: 34394096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-infiltrating lymphocytes in melanoma.
    Lee S; Margolin K
    Curr Oncol Rep; 2012 Oct; 14(5):468-74. PubMed ID: 22878966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Finding a place for tumor-specific T cells in targeted cancer therapy.
    Riddell SR
    J Exp Med; 2004 Dec; 200(12):1533-7. PubMed ID: 15611285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015--May 20-22, Vancouver, Canada.
    Boudreau JE; Wouters MC; Krawczyk CM
    Cancer Immunol Immunother; 2016 Feb; 65(2):235-41. PubMed ID: 26759005
    [No Abstract]   [Full Text] [Related]  

  • 27. Cell transfer-based immunotherapies in cancer: A review.
    Gorabi AM; Hajighasemi S; Sathyapalan T; Sahebkar A
    IUBMB Life; 2020 Apr; 72(4):790-800. PubMed ID: 31633881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive transfer of T-cell immunity.
    Kessels HW; Wolkers MC; Schumacher TN
    Trends Immunol; 2002 May; 23(5):264-9. PubMed ID: 12102748
    [No Abstract]   [Full Text] [Related]  

  • 29. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.
    Chicaybam L; Sodré AL; Bonamino M
    Int Rev Immunol; 2011; 30(5-6):294-311. PubMed ID: 22053970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.
    Kalbasi A; Shrimali RK; Chinnasamy D; Rosenberg SA
    J Immunother; 2010 Sep; 33(7):672-83. PubMed ID: 20664359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
    Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells.
    Eshhar Z
    Hum Gene Ther; 2014 Sep; 25(9):773-8. PubMed ID: 25244568
    [No Abstract]   [Full Text] [Related]  

  • 33. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.
    Li H; Zhao Y
    Protein Cell; 2017 Aug; 8(8):573-589. PubMed ID: 28434147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
    Melief CJ
    Adv Cancer Res; 1992; 58():143-75. PubMed ID: 1532109
    [No Abstract]   [Full Text] [Related]  

  • 35. Ex vivo gene transfer for improved adoptive immunotherapy of cancer.
    Ngo MC; Rooney CM; Howard JM; Heslop HE
    Hum Mol Genet; 2011 Apr; 20(R1):R93-9. PubMed ID: 21415041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One size does not fit all: personalized immune therapies poised to take center stage.
    Azvolinsky A
    J Natl Cancer Inst; 2013 May; 105(9):583-4. PubMed ID: 23591459
    [No Abstract]   [Full Text] [Related]  

  • 39. Chimeric antigen receptor T cell therapy: 25years in the making.
    Gill S; Maus MV; Porter DL
    Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
    Zhou J; Dudley ME; Rosenberg SA; Robbins PF
    J Immunother; 2005; 28(1):53-62. PubMed ID: 15614045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.